Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Catalyst Pharmaceuticals, Inc. - Common Stock
(NQ:
CPRX
)
26.26
+0.37 (+1.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Immunome Stock Sees RS Rating Jump To 91
↗
August 20, 2024
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
Via
Investor's Business Daily
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
August 20, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
↗
August 19, 2024
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.
Via
Investor's Business Daily
Top 3 Health Care Stocks That May Crash In August
↗
August 14, 2024
Via
Benzinga
The Latest Analyst Ratings For Catalyst Pharmaceuticals
↗
August 12, 2024
Via
Benzinga
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
↗
June 03, 2024
Via
Benzinga
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
↗
May 10, 2024
Via
Benzinga
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
↗
March 27, 2024
Via
Benzinga
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
↗
August 07, 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks You May Want To Dump This Quarter
↗
July 30, 2024
Via
Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
↗
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
July 24, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
July 22, 2024
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
↗
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
May 30, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
May 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
↗
May 15, 2024
These two healthcare stocks may be deeply undervalued.
Via
The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
↗
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
↗
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
↗
May 08, 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
↗
May 08, 2024
The company doubled Wall Street's earnings views, but sales came in short.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
May 01, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
April 22, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
March 28, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
↗
March 27, 2024
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Via
InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
↗
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
↗
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
